Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Clinical trial NCT07607418 · RECRUITING

Trial details

NCT number: NCT07607418
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)

Start date: 2026-05-22
Primary completion: 2027-05-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.